Latest news with #MIMEncore
Yahoo
16-06-2025
- Business
- Yahoo
GEHC Stock Declines Despite Expansion in Precision Care Capabilities
GE HealthCare Technologies Inc. GEHC, on Thursday, announced the combination of its proprietary features and algorithms with MIM Encore. Per management, the software solution has been designed to handle key healthcare challenges like improving efficiency, streamlining cross-departmental communication and reducing manual workloads. GE HealthCare acquired MIM Software in 2024. The latest move is expected to be a significant milestone for GE HealthCare with respect to delivering precision care through advanced digital solutions. This, in turn, is likely to boost its Molecular Imaging & Computed Tomography (CT) business and strengthen its foothold in the niche space. Following the announcement, shares of the company lost nearly 1.6% till Friday's trading. Historically, the company has gained a high level of synergies from its partnerships. Although the latest announcement is likely to be beneficial for GEHC's top-line growth going forward, the stock declined overall. GE HealthCare currently has a market capitalization of $33.08 billion. It has an earnings yield of 5.6%, better than the industry's 0.5%. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Per GE HealthCare, its first combined software release with MIM Encore will likely aid in enhancing digital imaging and workflow solutions across oncology, cardiology and neurology. MIM Encore, now equipped with additional GE HealthCare features and algorithms, is expected to deliver an integrated reporting experience for both positron emission tomography (PET) and SPECT (single-photon emission CT) imaging. Also, GE HealthCare's Effortless Workflow seamlessly integrates with MIM Encore, enabling clinicians to manage rising caseloads with intuitive interfaces, customizable displays and automation that can help bridge experience gaps and reduce burnout. Per a report by Grand View Research, the global molecular imaging market was valued at $8.8 billion in 2024 and is anticipated to witness a CAGR of 4.6% between 2025 and 2030. Factors like the increasing prevalence of chronic diseases, such as cancer, the therapeutic sectors, and the development of hybrid imaging systems are likely to drive the market. Given the market potential, the latest advancement in precision care is expected to provide a significant boost to GE HealthCare's business. This month, GE HealthCare and PT Kalbe Farma Tbk (Kalbe) have officially inaugurated Indonesia's first production facility dedicated to manufacturing technologically advanced CT scanners. Last month, GE HealthCare announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for clinicians now recommend considering fluoroestradiol (FES) PET for systemic staging in patients with recurrent or metastatic lobular breast cancer. The same month, GE HealthCare received the FDA's 510(k) clearance for its Aurora nuclear medicine system and Clarify DL. Shares of the company have lost 6.8% in the past year against the industry's 10.1% rise and the S&P 500's gain of 9.4%. Image Source: Zacks Investment Research Currently, GEHC carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Cencora, Inc. COR and Integer Holdings Corporation ITGR. Hims & Hers, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 36.5%. HIMS's earnings surpassed estimates in two of the trailing four quarters, missed once and broke even in the other, the average surprise being 19.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Hims & Hers' shares have surged 129.7% compared with the industry's 36.1% gain in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora has rallied 25.9% against the industry's 16% decline in the past year. Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings' shares have gained 0.9% against the industry's 14.2% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
12-06-2025
- Business
- Business Wire
GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare's proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagnostic confidence, streamline workflows, and support the future of personalized medicine. 'In today's rapidly evolving healthcare landscape, operational efficiency and seamless collaboration are not just goals — they're the cornerstone to success. That's why we aim to provide tools that can help enhance providers' confidence in decision making and support patients in receiving personalized care,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We are committed to delivering technology that unifies data across systems and organizations, breaking down workflow barriers to help drive better clinical outcomes and elevate the standard of patient care.' New capabilities now available to GE HealthCare, MIM Software customers Now featuring dedicated post-processing tools for GE HealthCare systems, MIM Encore helps deliver excellent image quality with minimal effort, streamlining everyday nuclear medicine and cardiology workflows. Users can expect high image quality with minimal effort, along with automated read preparation, structured reporting, and flexible interpretation tools for PET/CT, SPECT/CT, and multi-modality fusion — all in a single platform. MIM Encore empowers clinicians and researchers to help deliver fast, accurate diagnoses, and onboard users quickly, for efficiencies and consistencies in work and communication between clinicians. 'Customers are telling us that this pairing is exactly what users have been looking for. The combined solution enables streamlined, accurate reading of images, supports quantitative analysis out of the box, and helps eliminate manual entries,' says Andrew Nelson, CEO, MIM Software, a GE HealthCare Company. 'As we continue to evolve our vertically integrated products based on user input, we remain focused on creating a user-friendly, vendor-neutral, future ready experience designed to scale with advanced molecular imaging needs.' With easy adoption across departments and roles — as well as few manual steps — MIM Encore adds resolution recovery and image-enhancing tools tailored for GE HealthCare scanners, streamlining workflows while helping elevate diagnostic confidence across care areas. Oncology: MIM Software's tools, now paired with GE HealthCare systems, simplify SPECT image processing with reconstruction and configurable enhancements, including resolution recovery, attenuation and scatter correction, advanced filtering, and motion correction. As a result, clinicians can view dynamic and static scans, share images easily, and access advanced quantitation tools — helping deliver clear insights with less manual effort. Cardiology: GE HealthCare's cardiac imaging is now even stronger with MIM technology's advanced PET and SPECT tools, enabling fast, high-quality reconstructions and quantitative analysis. Features like motion correction, automated quality checks, and intuitive displays help deliver accurate and efficient cardiac care. With support for key radiotracers and advanced algorithms like Evolution for Cardiac — developed at Johns Hopkins and University of North Carolina — MIM Encore is designed to deliver high-quality images at reduced acquisition times or doses i. Neurology: As a leader in neurodegenerative imaging, GE HealthCare with MIM technology now offers reconstruction workflows with 3D rendering and advanced corrections. As a result, clinicians benefit from consistent, high-quality images and easy-to-use tools for confident diagnosis, and assistance in treatment planning and evaluation. Also new, GE HealthCare's Effortless Workflow seamlessly integrates with MIM Encore, enabling clinicians to manage rising caseloads with intuitive interfaces, customizable displays, and automation that can help bridge experience gaps and reduces burnout. GE HealthCare acquired MIM Software in 2024, bringing together two industry leaders with expertise in multi-modality imaging, quantitation, workflow automation and molecular imaging. For more information on GE HealthCare's molecular imaging portfolio – including MIM Encore – please visit and SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
